Oncology for the Inquisitive Mind has been privileged to interview some truly brilliant specialists, and this week's guest is no exception. Professor Anthony Joshua is the Head of Oncology at the Kinghorn Cancer Centre and St Vincent's Health in Sydney. He is a globally recognised expert in genitourinary cancers and melanoma, with a special interest in ocular melanoma.

Professor Joshua completed his PhD in prostatic carcinogenesis under the supervision of Dr Jeremy Squire and a clinical fellowship under Dr Ian Tannock. He worked at Princess Margaret Cancer Centre before returning down under and has helped reshape cancer care at the Kinghorn Cancer Centre, making it one of the largest trial centres in New South Wales. Today, Professor Joshua discusses his journey, the landscape of prostate cancer, and some of his research in the area of ocular melanoma.

Professor Anthony Joshua is not a professional British boxer. To find out more about Professor Anthony Joshua's research portfolio, click here

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Spotify Link to Prof Joshua's podcast, Dangerous Ideas in Drug Development: https://podcasters.spotify.com/pod/show/necta

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Oncolytic viruses thrive in cancer cells and can replicate rapidly, destroying the cells and enabling the immune system to attack tumours. This week, we interview Dr Malcolm McColl and Prof Darren Shafren, a dynamic duo in Australian biotechnology and part of the leadership team of ImmVirx, a viral oncolytic company. Prior to creating ImmVirx, they successfully launched the product Cavatak, used in melanoma and other malignancies.

ImmVirx has developed a proprietary bio-selected RNA virus that is showing promising pre-clinical and phase 1 results as monotherapy in hard-to-treat cancers, including colorectal, gastric hepatocellular and ovarian cancers.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.

Links to studies discussed in this episode (subscription may be required):

BEAT-meso: Link

Checkmate 816 4 year update: Link

MIST5: Link

ctDNA-Lung-DETECT: Link

BEAT-SC: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Every feast needs a palate cleanser. Every great work of theatre needs an intermission. Every sports event needs a half-time show. In this way, Oncology for the Inquisitive Mind is no different to Hamilton or the Super Bowl. Here, we provide a little deviation from our ongoing Prostate Cancer Saga to interview Dr Jenny Liu, Oncologist and early drug development (EDD) researcher extraordinaire. Our discussions range from her slightly unusual path to oncology, her previous research and how it is still making waves in the oncological community, and her other great passion: mentorship. Suppose you are interested in Phase One trials, mentorship opportunities (especially in Australia), or simply enjoy Josh dredging up dirt on highly accomplished clinicians. In that case, this is the episode for you!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In the second episode of our prostate-cancer series, we investigate the inevitability of castration resistance: the biochemical, radiological and clinical progression of prostate cancer despite the best efforts of the heroic MDT. While this space will likely change in the coming years, with many novel anti-androgen agents displaying efficacy in the HSPC space, the current standards of care for patients include docetaxel and the dynamic duo of abiraterone + prednisolone and enzalutamide. These latter two agents are frequently used in the first line when a patient cannot or is unlikely to tolerate docetaxel chemotherapy.

However, there can only be one Lord of the Anti-Androgens, and today Josh and Michael will reveal their preferred agent. Listen on to find out which, and please, contain your excitement.

Links to studies discussed in this episode (subscription may be required):

1. PREVAIL: https://www.nejm.org/doi/full/10.1056/nejmoa1405095
2. COU-AA-302: https://www.nejm.org/doi/full/10.1056/nejmoa1209096
3. TAX-327 (cameo only): https://www.nejm.org/doi/full/10.1056/nejmoa040720

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Endocrinopathies in immunotherapy-related cancer treatment are common! Most of us will experience patients with hyperthyroidism and hypothyroidism regularly and recurrently in everyday practice. The incidence is variable, with some sources stating as high as 40% and others as low as 10%; either way, oncologists and trainees are likely to be close allies with their friendly neighbourhood endocrinologist. This week on Oncosnacks, Michael and Josh are interviewing Dr Dahlia Davidoff, an endocrinologist at North Shore Private Hospital in Sydney. Dahlia completed her specialist training through the prestigious Alfred Health and is currently a PhD student researching endocrine cancers at the Kolling Institute of the University of Sydney.

They focus predominantly on thyroid disorders and how to diagnose and optimise these conditions with patients receiving immunotherapy

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Dahlia Davidoff details:

https://www.davidoffendocrinology.com/

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

J.R.R. Tolkien. George Lucas. Steven Spielberg. With such seminal trilogies as Star Wars, the Lord of the Rings and Indiana Jones achieving a permanent place in the psyche of everyday life, who would have thought there would be room for more? But fear not, because Michael and Josh are here with their take on the age-old formula, with the first in a trilogy of episodes on prostate cancer. Just as Luke Skywalker discovered his heritage and embarked on an epic quest against the Empire, so too do our heroes take their first steps in a fight of their own, examining two studies that pave the way for the future in hormone-sensitive prostate cancer (HSPC) treatment. Gone are the days of ADT-alone, fading to give way to a newer, brighter future, like the end of Tolkien's Third Age. In summary, one may say of the old vogue of HSPC treatments: "It belongs in a museum!"

Have we mentioned that we are MASSIVE nerds recently?

Links to studies discussed in this episode (subscription may be required):

1. ARASENS: https://www.nejm.org/doi/full/10.1056/NEJMoa2119115
2. PEACE-1: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00367-1/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Ageism is an inherent bias seen throughout medicine, with cancer adding complexity to an already difficult set of circumstances. Despite our best efforts, we all must face growing older, with time itself being that unstoppable force. Over 50% of all new cancer diagnoses are in the over-65 age bracket, which will climb as ageing populations become a reality across the globe.

This week, Michael and Josh interview the charismatically delightful Dr Michael Krasovitksy, a staunch supporter and advocate of self-empowerment, geriatric oncology and self-determination in the oncological world. Multiple thought-provoking topics are covered, including ageism, toxicity, symptom management, geriatric oncology, holistic medicine and how to combat the creeping presence of frailty. We also debate the age-old question: When do we not treat, and how does one have this conversation with the outcome being a guaranteed ticket to "shuffle off this mortal coil"?

This is one episode where Michael and Josh might find themselves with more questions than answers.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Hosted on Acast. See acast.com/privacy for more information.

This episode of OncoSnacks pays homage to the lack of eyebrows, eyelashes and hair many patients face when undergoing cancer treatment and the resultant alopecia. While chemotherapy is the most wanted agent, it alone is not to blame. Michael and Josh explore the hairy situation of hair loss that faces many of our patients as they navigate a new world of outpatient clinic appointments, infusion centres and a new reality in how they live and look.

No eyebrows were injured during the making of this episode.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

Today, our intrepid trio once more plunge down 20,000 leagues, exploring the confusing depths, hoping to answer one question: is there any evidence to support using systemic therapy in patients with potentially resectable oligometastatic colorectal cancer? The answer will take them to many dark, barely-explored corners of their profession and will raise more questions than answers. Following in the forebears of many explorers, it may drive them completely mad, or at least madder than they already are. But, to paraphrase Captain Nemo of the Nautilus: "the Earth does not want new continents, but new evidence for patients with resectable metastatic colorectal cancer."

Links to studies discussed in this episode (subscription may be required):

OLIVIA: https://www.annalsofoncology.org/article/S0923-7534(19)31451-6/fulltext#ec0035

Falcone et al.: https://ascopubs.org/doi/10.1200/JCO.2006.09.0928?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

TRIBE: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00122- /fulltext#:~:text=TRIBE%20was%20an%20open%2Dlabel,were%20recruited%20from%2034%20Italian

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Michael and Josh welcome back Dr Andrew Jensen to help explore part two of OftiM's Head and Neck Cancer exploration party. With localised treatments done and dusted, the metastatic space is a daunting heterogeneous disease group. Twenty years ago, head and neck treatment relied on tried and true chemotherapy, but the last fifteen years have shown great strides regarding treatment options and outcomes. The first leap forward was cetuximab added to a chemotherapy backbone, making it the weapon of choice for oncologists worldwide. But like all great civilisations, pembrolizumab now dominates, showing how it can be effective when combined with existing treatment options.

A star-studded episode and one not to be missed!

Links to studies discussed in this episode (subscription may be required):

1. NCT00122460- https://www.nejm.org/doi/full/10.1056/nejmoa0802656
2. Keynote 048- https://www.thelancet.com/article/S0140-6736(19)32591-7/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Hosted on Acast. See acast.com/privacy for more information.

30 episodes ago, two young doctors took their first steps into the podcasting sphere, stumbling like two newborn foals birthed into a paddock full of fully functioning stallions, presenting a niche. Since then, they have blossomed before your ears into two vaguely competent podcasters, still finding their feet but growing in confidence, if not skill. Our continued existence, we owe entirely to you, our wonderful audience. You are the reason we continue to front up to our microphones every week, often wearing our pyjamas but that's beside the point. What we're trying to say is thank you, from the bottom of our hearts.

To express our gratitude, we have prepared a niche episode for our niche podcast, examining the treatment of early head and neck cancer. This topic can befuddle even the most experienced oncologists with its confusing, contradictory cornucopia of confirmatory cancer clues. So listen on, as Michael and Josh try to clear a path through the dense jungle, like Doctor Livingstone BEFORE he went missing. Have I met my metaphor quota yet?

Links to studies discussed in this episode (subscription may be required):

JCOG1008: https://ascopubs.org/doi/full/10.1200/JCO.21.01293

Induction chemotherapy for NPC (Zhang et al.): https://www.nejm.org/doi/10.1056/NEJMoa1905287?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

This episode of OncoSnacks kicks off Michael and Josh's sojourn into the wide world of immune-mediated adverse effects. Inevitably, as most blowhards do, they begin with the lungs. Immune-mediated pneumonitis is not as common as endocrine-axis abnormalities, dermatitis or colitis, but it can be insidious and devastating in equal measure. Such is the potential impact that must be considered in any patient who has received immunotherapy and presents with dyspnoea or a dry cough. Listen to learn more, and you will also know what irAEs and Senator Joseph McCarthy have in common.

Guidelines for the management of Immune-Mediated Pneumonitis are available at:

• https://www.frontiersin.org/articles/10.3389/fonc.2020.01785/full#:~:text=will%20be%20discussed.-,Incidence%20and%20Risk%20Factors,due%20to%20pneumonitis%20(6)
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161534/
• https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/immunological/1993-management-of-immune-related-adverse-events

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel, viral-driven vector that aims to increase the immune response to treatment, potential treatment for the very rare nasal squamous cell cancer, data supporting the treatment of patients with poor prognosis and head and neck patients, and a new, intensive immunotherapy treatment for nasopharyngeal cancer. A wide variety of studies that are sure to satisfy a broad range of palates!

Links to studies discussed in this episode (subscription may be required):

TARGET-HPV: Link

Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status: Link

KCSG HN18-07: Link

Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial: LinkFor more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Five hundred years ago, Christopher Columbus set forth to explore unknown lands. You might be asking, what do Chris and metastatic hormone receptor-positive breast cancer have in common? The answer lies in his diaries, a tale of two men, with one aptly providing anatomical details of our subject today. While we spend little time exploring Christopher, Michael and Josh meet and greet three famed Cyclin Dependant Kinase Inhibitors (CDK4/6) commonly known as Ribociclib, Abemaciclib and Palbociclib. While not all equal in stature, they have revolutionised metastatic breast cancer and now stand as first-line therapy and the gold standard of treatment. Tune in to find out why!

Visit us at your new website, www.inquisitiveonc.com, for our latest episodes, links to resources and musings!

Find us on Twitter @InquisitiveOnc

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver. Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice, and for health, practitioners ensure you refer to your local institution's guidelines for treatment recommendations.

Hosted on Acast. See acast.com/privacy for more information.

For the second time in 2023, Josh and Michael discuss some of the hardest-hitting highlights from a conference; in this case, they dive into five studies that caught their eye at the recent ASCO GU Conference in, in Michael's words, "sunny California." We think he is simply jealous of the fact that Melbourne barely has sunshine for most of the year. Never fear: the amount of grousing about the weather pales in comparison to the clinical pearls, future projections and terrible puns.

Studies Discussed: ARASENS, CaboPoint, TALAPRO, HCRN GU14-188, PROpel, TROPHY-U-01, CAPTURE

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Note: This podcast is for educational purposes only. If you are unwell, seek medical advice, and for health, practitioners ensure you refer to your local institution's guidelines for treatment recommendations.

Hosted on Acast. See acast.com/privacy for more information.

In this episode of OncoSnacks, Josh and Michael address the classic chemotherapy side effect: nausea. From Terms of Endearment (1983) to ER (2002), from Breaking Bad (2008) to Archer (2011), nausea and vomiting are the most frequently imagined side effects when it comes to chemotherapy. However, we are much better at managing chemotherapy-induced nausea and vomiting (CINV) than we once were; a combination of better antiemetics and move away from highly emetic therapies means patients are usually much better off perspective. Nevertheless, in the words of great ancient oncologist Sun Tzu: "if one knows oneself, and knows the neuronal pathways associated with chemotherapy-induced nausea and vomiting, one need not fear the result of a thousand infusions." Listen on to find out how!

Guidelines for management of CINV available at:

- https://www.sciencedirect.com/science/article/pii/S2468294220301131

- https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/7-prevention-of-anti-cancer-therapy-induced-nausea

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Note: This podcast is for educational purposes only. If you are unwell seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

Concluding their Journey to the Centre of the Brain, Michael and Josh tackle one of the most challenging and difficult cancers in modern oncology: high-grade gliomas. All of the usual suspects are here: irrevocable, progressive disease, limited treatment options and a gulf in evidence so large it makes the Grand Canyon look like a muddy footprint. All in all, not the most optimistic of OftiM episodes, but Josh and Michael will tackle it anyway so you don't have to. And remember: always refer your fit GBM patients to a friendly neighbourhood trials unit near you!

Links to studies discussed in this episode (subscription may be required):

EORTC 26981-22981 NCIC CE3 (aka the “Stupp study"): https://www.nejm.org/doi/full/10.1056/nejmoa043330

RTOG 0825: https://www.nejm.org/doi/full/10.1056/nejmoa1308573

Brada et al: https://ascopubs.org/doi/full/10.1200/JCO.2009.27.1932?role=tab

Taal et al: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70314-6/fulltext

Wick et al: https://www.nejm.org/doi/full/10.1056/nejmoa1707358

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Visit us at your new website www.inquisitiveonc.com for our latest episodes, links to resources and musings!

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Note: This podcast is for educational purposes only. If you are unwell seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

Oncology for the Inquisitive Mind finally embarks on the treacherous journey of neuro-oncology. While researching for this episode, Michael and Josh realised that effective treatments are limited but do not reduce neuro-oncology's complexity. This is a hefty episode covering low-grade gliomas, oligodendroglioma, astrocytomas and the important molecular markers and how these influence survival and prognosis for our patients. It also talks about the new WHO classification of primary brain tumours and how it has affected the interpretation of prior research.

Tune in for part one of this special mini-series covering neuro-oncology

Link: https://www.atlasantibodies.com/blog/glioma-classification-and-key-molecular-pathology/

• External site, no subscription is required

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Note: This podcast is for educational purposes only. If you are unwell seek medical advice

Hosted on Acast. See acast.com/privacy for more information.

In our second bite-sized episode, Michael and Josh explore the challenge of chemotherapy-induced diarrhoea, a common problem for patients leading to morbidity, hospital admissions, and potentially stopping curative treatments early. While immunotherapy and targeted therapy are not innocent bystanders regarding colitis and bowel problems, chemotherapy has long been the most prominent protagonist of this story. It is essential to identify warning signs, investigate adequately and see the treatment options available to you, the saviour and potential part-time plumber. Tune in and find out more!

eviQ reference guide on diarrhea: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/779-treatment-induced-diarrhoea#:~:text=Chemotherapy%2Dinduced%20diarrhoea%20usually%20occurs,cause%20diarrhoea%20at%20other%20times.

BC Cancer reference guide on diarrhea:

http://www.bccancer.bc.ca/nursing-site/Documents/4.%20Diarrhea.pdf

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In the grand, six-month-long tradition of Oncology for the Inquisitive Mind, Josh and Michael provide an update from an international meeting to keep you right up to date with the latest and greatest developments in their field. This week's special is the ASCO GI Symposium, held in Moscone, California, and brought to your ears from Melbourne. From two guys in their pyjamas. Who would much rather be in Moscone, California.

At any rate, updates abound in this OftiM special. Listen on so you too can crest the wave of Gastrointestinal Oncology!

Studies Discussed: NAPOLI 3, CHECKMATE 648 and 649 updates, SPOTLIGHT, Pemigatinib in FGFR mutant mCRC

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Oncology for the Inquisitive Mind returns to its regular broadcasting schedule and discusses metastatic renal cell cancer (ccRCC). As not to be outdone, Josh takes a cultural tangent exploring the world of opera after seeing "The Hours" broadcast through Met: Live in HD. While Josh doesn't sing this episode, he highlights this opera's parallels with cancer patients undergoing treatment. To avoid losing sight of this podcast's purpose, Michael and Josh soon find their way. They discovered that metastatic renal cell carcinoma has many treatment options, including targeted therapy, immunotherapy, or even combining these two modalities! Tune in to find out where the evidence currently stands.

Links to studies discussed in this episode (subscription may be required):

CHECKMATE 214: https://www.nejm.org/doi/full/10.1056/nejmoa1712126

KEYNOTE-426: https://www.nejm.org/doi/full/10.1056/NEJMoa1816714 

Other studies of interest:

CLEAR: https://www.nejm.org/doi/full/10.1056/NEJMoa2035716

CheckMate 9ER: https://www.nejm.org/doi/full/10.1056/nejmoa2026982

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

This is OncoSnacks, a new, fortnightly OftIM spinoff!

In this new bite-sized series, Michael and Josh try to sink their teeth into more slice-of-life topics, all to help you, our beloved listeners, digest some of the most common problems your patients will serve to you on a platter. This week, a treatment side effect that actually stops people eating (and making lame food-based puns as well): mucositis.

This common side effect of anti-cancer systemic therapy can have a major impact on patients quality of life, frequently leading to hospitalisations, significant morbidity and nasogastric tubes galore. But how do we manage such a troublesome problem? Listen on to find out!

eviQ reference guide on mucositis: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/oropharyngeal/210-oral-mucositis-and-stomatitis

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

This week on Oncology for the Inquisitive Mind, Michael dons his cultural hat and begins with an Ode to the Kidneys, organs that are as much a muse for poets worldwide as the heart (probably). However, you didn't come to this podcast for excellent poetry being delivered with all the panache and misguided enthusiasm of a walrus stepping on a piece of LEGO, and Michael and Josh aim to deliver on this front. Our intrepid pair examine the controversial world of adjuvant treatment of clear cell renal cell cancers (ccRCC), an area of research littered with the ghosts of negative or equivocal studies. But, not every study can be a FLAURA or a DESTINY, and negative studies are just as important, so listen on to find out exactly what NOT to do. Truly, an OftIM first!

Links to studies discussed in this episode (subscription may be required):

ASSURE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591751/

KEYNOTE-564: https://www.nejm.org/doi/full/10.1056/NEJMoa2106391

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colon space with sintilimab and IBI310 battling it out with the old master pembrolizumab. The rectal contingent is the TNTCRT trial, looking at total neoadjuvant therapy vs concurrent chemoradiotherapy. While the world may have moved forward, this trial could provide further evidence of the path we should be taking.

Links to studies discussed in this episode (subscription may be required)

NEOPRISM-CRC: Link

TNTCRC: Link

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labelled, phase Ib study: Link

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

As the southern hemisphere basks in summer's beautiful warmth, Michael and Josh skip the beach to explore skin cancer. While melanoma usually takes centre stage in the oncological world, it is far less common than basal cell carcinoma or squamous cell carcinoma. Metastatic squamous cell carcinoma now has a viable and effective treatment option called cemiplimab. At the other end of the spectrum, Michael investigates the very rare cancer type Merkle Cell Carcinoma and how Avelumab has changed its treatment paradigm. Once again, it's immunotherapy at its best. So remember, while listening to our podcast, don't forget to wear a hat and apply sunscreen generously!

Links to studies discussed in this episode (subscription may be required):

Migden et al. (Cemiplimab): https://www.nejm.org/doi/10.1056/NEJMoa1805131?url_ver=Z39.88

JAVELIN Merkel 200 (Cohort B): https://jitc.bmj.com/content/9/7/e002646

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

New year, new episode of Oncology for the Inquisitive Mind! After enjoying their holiday break, Josh and Michael dive right into 2023 with an episode especially aimed at trainees just about to start their new professional journey in Medical Oncology. Joined by an old friend, the wise-beyond-his-years Dr Andrew Jensen, they discuss life as a trainee, balancing work and life, and how to navigate the tough first few years of life in training, which can so often feel like being a bottle cast into a storm. Join us for an episode that may be light on hazard ratios and p values, but heavy on practical tips and wisdom, delivered in the tone of three dads drinking beer by a campfire...

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Oncologists love pushing the limits of what is possible for our patients. To celebrate this and the 20th episode of Oncology for the Inquisitive Mind, Michael and Josh explore the heights of pioneering treatment for early-stage triple-negative breast cancer (TNBC). A notoriously resistant cancer with no known targetable lesions that affect younger women on average, The BrighTNess trial, Keynote 522 and Create-X show just how far the treatment landscape has changed in the last five years.

Tune into our final episode for the year! We will return in early 2023 with more content, interviews and hilarious banter.

On a final note, Dr Michael Fernando has been admitted to the Royal Australian College of Physicians (RACP), the equivalent of being board certified! Michael has completed this arduous training and is now a fully-fledged Medical Oncologist! Do not distress listeners. Despite no longer being a trainee, Michael will continue on as presenter and host extraordinaire for this podcast.

Links to studies discussed in this episode (subscription may be required):

BrighTNess trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30111-6/fulltext

Keynote 522: https://www.nejm.org/doi/full/10.1056/NEJMoa1910549

Create-X: https://www.nejm.org/doi/full/10.1056/NEJMoa1612645

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

"I'm not in danger; I AM the danger!" So said Bryan Cranston's Walter White, and so too said early-stage lung cancer when confronted with adjuvant chemotherapy (maybe). In this episode, however, Josh and Michael follow in the footsteps of Hank Schrader, Steve Gomez et al., discussing ways to tackle one of the biggest killers in oncology. While we may not have found a way to control early-stage lung cancer, new developments are on the horizon, such as neoadjuvant chemo-immunotherapy and adjuvant osimertinib. So listen on, with the disclaimer that any similarities between Walter White and Jane Eyre are purely coincidental, no matter what Josh may argue...

Links to studies discussed in this episode (subscription may be required):

CHECKMATE-816: https://www.nejm.org/doi/10.1056/NEJMoa2202170

ADAURA: https://www.nejm.org/doi/full/10.1056/NEJMoa2027071

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Mikey travel back millions of years to a time when dinosaurs roamed the Earth, as recent research has demonstrated, unmolested by cancer. Then they come crashing back to the present to discuss this week's topic, metastatic colorectal cancer. Will they discover secrets hidden across the aeons? Was the secret to cancer treatment hidden in the bones of our scaled precursors? No, of course not. But there will be a lot of information on the improving treatment of colorectal cancer, which has not taken millions of years to advance. Oh, and Michael does a passable Richard Attenborough.

Links to studies discussed in this episode (subscription may be required):

FIRE-3: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70330-4/fulltext

KEYNOTE 177: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699

BEACON: https://www.nejm.org/doi/full/10.1056/NEJMoa1908075

Epidemiological Study of Tumours in Dinosaurs: https://link.springer.com/article/10.1007/s00114-003-0473-9

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Movember is an important event focussing on men's health, including cancer. Prostate cancer is the most common male cancer diagnosed in Australia and the second most common in American men. To highlight this and explore the pioneering treatments available, Michael and Josh interviewed the esteemed Dr Megan Crumbaker. Megan is a medical oncologist specialising in genitourinary cancer and works at The Kinghorn Cancer Centre and St. Vincents Health in Sydney, Australia. Dr Crumbaker completed her undergraduate at Rice University, Texas, before completing her medical training in Sydney and a PhD in prostate genomics through The Garvan Research Institute.

We discussed all things prostate oncology with Megan, including research, career, pioneering treatment options and all things prostate cancer. These treatment pearls are not to be missed by any budding oncologist!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

After looking at early upper gastrointestinal cancers last week, Michael and Josh take the logical next step and discuss the management of their metastatic cousins, the most unsavoury collection since Cassius and Brutus teamed up to assassinate their erstwhile friend Julius. And while our weapons against these cancers are limited, that will not stop our intrepid podcasting pair from taking a deep, rambling and irreverent dive into the dirty details. Friends! Oncologists! Countrymen! Lend us your ears!

Links to studies discussed in this episode (subscription may be required):

TOGA: https://www.thelancet.com/article/S0140-6736(10)61121-X/fulltext

CHECKMATE 649: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00797-2/fulltext

CHECKMATE 648: https://www.nejm.org/doi/full/10.1056/NEJMoa2111380

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

As we CROSS into another episode, Michael and Josh explore the world of early gastric cancer and esophageal cancer. Interestingly both these cancers have a higher incidence in Asia and North Africa. Your podcast hosts soon find early detection of these cancers can be difficult, often leading to treatment challenges not seen by other cancer streams, such as bowel or breast cancer. Unlike previous episodes, FLOT4 looks at perioperative chemotherapy and its benefits over the previous incumbent chemotherapy. Before we give anything more away, make sure to listen to this episode to understand the gold standard of care for these cancers. Likes to the trials below!

Links to studies discussed in this episode (subscription may be required):

CROSS: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00040-6/fulltex

FLOT4: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32557-1/fulltext

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

After the highs of their special interview with Dr Belinda Yeo on all things breast cancer, Josh and Michael crash back to their usual programming with a banter and dad-joke-filled journey through the treatment of advanced ovarian cancer. A notoriously insidious disease, ovarian cancer is responsible for not just significant mortality but soul-crushing morbidity as well. However, for some very special people, ovarian cancer does not stop them from reaching their goals, up to and including completing a triathlon! Listen on for the full, inspiring story!

Links to studies discussed in this episode (subscription may be required):

PAOLA-1: https://www.nejm.org/doi/full/10.1056/nejmoa1911361

AURELIA: https://ascopubs.org/doi/10.1200/jco.2013.51.4489

Leslie Medley-Russell, Ovarian Cancer Survivor: https://www.mdanderson.org/cancerwise/two-time-ovarian-cancer-survivor--never-give-up.h00-159148401.html

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

To celebrate the end of breast cancer awareness month, Michael and Josh are joined by Dr Belinda Yeo, an experienced oncologist specialising in treating breast cancer. Belinda trained at St Vincent's Hospital in Sydney, Australia, followed by the Royal Marsden Hospital in London. She now works at the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer and the prestigious Austin Hospital in Melbourne, Australia.

We discussed all things breast oncology with Belinda, including career path, research, patient-centred care and, of course, all the breast cancer treatment pearls for any budding oncologist!

This is one episode not to miss!

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically meaningful KRAS and BRAF mutation pathways and most recently with the potential for immunotherapy in the deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) subgroups. In this episode, Josh and Michael examine studies looking at KRAS G12C-mutated, HER2-positive and dMMR colorectal cancer, as well as a very exciting study examining the utility of transplantation in patients with liver-only colorectal metastases.

Links to studies discussed in this episode (subscription may be required):

CODEBREAK300: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=234200%23234200 

MOUNTAINEER: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=231646%23231646  

CHECKMATE 8HW: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231645%23231645

TRANSMET: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231641%23231641

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael take a step down from the dizzying heights of HER-2 positive breast cancer treatment and crash back to earth to metastatic pancreatic cancer, a topic that remains an unconquered Everest, mocking oncologists like that one kid who always stole Josh's lunch money in school... Don't worry; there will be no airing of childhood trauma here. Just two oncologists discussing treatments and casting a hopeful eye towards the future.

Links to studies discussed in this episode (subscription may be required):

ACCORD-11: https://www.nejm.org/doi/full/10.1056/nejmoa1011923

MPACT: https://www.nejm.org/doi/full/10.1056/nejmoa1304369

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In part two of their HER2 breast cancer dive, Josh and Michael explore the optimistic world of metastatic breast cancer. Once a desolate space with limited options, HER2 metastatic breast cancer represents the frontier of targeted therapy, like the industrial age or landing on the moon. While neither Josh nor Mikey have been to the moon, these researchers have landed among the stars bringing hope and effective treatments to an aggressive tumour time that a decade ago would have had a very different story. 

Links to studies discussed in this episode (subscription may be required):

CLEOPATRA: https://www.nejm.org/doi/full/10.1056/nejmoa1413513

Destiny-Beast03: https://www.nejm.org/doi/10.1056/NEJMoa2115022

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael begin their second two-part expedition, this time exploring HER2-positive breast cancer, an area of oncology that has been much like your favourite Instagram or TikTok celebrity: at the forefront of the hottest new trends. Neither Josh nor Mikey have a favourite Instagram or TikTok celebrity because they are old and out of touch, but the shifts in HER2-positive breast cancer may be their favourite oncological TikTok celebrity. For the reasons behind such a stretched analogy, listen on!

Links to studies discussed in this episode (subscription may be required):

NeoSphere: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70336-9/fulltext

KATHERINE: https://www.nejm.org/doi/full/10.1056/nejmoa1814017

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael once again tackle immunotherapy in its application to metastatic urothelial cancer. Some say immunotherapy should be used up front. Others say that it should be used when all previous treatments have failed. And still, others are wondering about that Richard Nixon/Spock impression from last week and how it could be topped. For answers to all those questions and more, you'll have to listen on...

Links to papers discussed in this episode (subscription may be required):

JAVELIN-100: https://www.nejm.org/doi/full/10.1056/NEJMoa2002788

KEYNOTE 045: https://www.nejm.org/doi/full/10.1056/nejmoa1613683

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this extraordinary episode, Josh and Michael continue their journey to the earth's centre and the unknown with more European Society of Medical Oncology (ESMO) highlights. 

Since last week, Michael has realised that his French needs a bit of work, so they stuck to their guns and avoided google translate. Josh feels they should work on their Spanish to prepare for ESMO in Madrid in 2023. But before these dashing young Doctors get too excited for next year, more pivotal studies must be reported for your enjoyment! This episode focuses on colorectal, and Michael dabbles in some genitourinary and skin research.

Find us @InquisitiveOnc for fun oncology facts and links to the latest episodes!

All abstracts discussed in this episode are available from https://oncologypro.esmo.org. ESMO membership may be required.

Colorectal: FRESCO-2, NICHE-2, MOUNTAINEER, CAIRO5

Genitourinary: RADICALS-HD, COSMIC 313;

Skin: SWOG1801; Neoadjuvant Cemiplimab (NEJM)

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this very special episode, Josh and Michael hope to fulfil their fantasy of attending the European Society of Medical Oncology's (ESMO) yearly Congress, where they rub elbows with oncology's biggest movers and shakers; learn about the latest groundbreaking studies; and, in Michael's case, speak French with an accent lifted from a Monty Python sketch. The fact that they were stuck at home for the entire conference won't stand in the way of them from highlighting some of the best, most exciting studies presented in Paris.

Find us @InquisitiveOnc for fun oncology facts and links to the latest episodes!

All abstracts discussed in this episode are available from https://oncologypro.esmo.org. ESMO membership may be required.

Lung: ADAURA, CODEBREAK 200, INCREASE, IPSOS, Checkmate 816, APPLE

Breast: BELLINI, TROPiCS-02

Upper GI: LEAP-002, PRODIGE-65-UCGI-36-GEMPAX, RLY-4008

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Fanfare theme courtesy of StudioKolomna: https://pixabay.com/users/studiokolomna-2073170/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

"Hepatobiliary cancer, the final frontier." So begins our double-headed sojourn into two of the most challenging to-treat cancers many oncologists will encounter, but one that ends on a surprisingly positive note. Also, there's a cameo that absolutely no one will see coming...

Links to studies discussed in this episode (subscription may be required):

TOPAZ-1: https://evidence.nejm.org/doi/full/10.1056/EVIDoa220001

IMbrave150: https://www.nejm.org/doi/10.1056/NEJMoa1915745

Barcelona Liver Cancer Staging: https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fb5943f9-9201-4128-848a-626d744c651f/gr1_lrg.jpg

Source: Reig M, et al. "BCLC strategy for prognosis prediction and treatment recommendation: the 2022 Update." Journal of Hepatology. November 2021. Available from: https://doi.org/10.1016/j.jhep.2021.11.018

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In episode 5, Michael and Josh dive into the complex world of hormone receptor-positive breast cancer. While early-stage breast cancer boasts fantastic cure rates many other cancers can only dream of, this evolving space must contend with multiple players, including aromatase inhibitors, tamoxifen and now abemaciclib (CDK 4/6 inhibitor). How best to approach adjuvant endocrine therapy is difficult, but Michael and Josh are on the case!

Links to papers discussed in this episode (subscription may be required):

SOFT/TEXT: Prudence et al. (2018): https://www.nejm.org/doi/full/10.1056/NEJMoa1803164

MonarchE: Johnston et al. (2020): https://pubmed.ncbi.nlm.nih.gov/32954927/

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Four episodes already! How time flies when you're having fun. In this episode, Josh and Michael discuss metastatic lung cancer, an area of oncology where a survival benefit of a few months generates cheers, tears and standing ovations. So what happens when studies start to improve patients' outcomes by YEARS? I don't know, but there were almost certainly minds that were thoroughly blown. Join us for this most optimistic of episodes!

Links to papers discussed in this episode (subscription may be required):

KEYNOTE-189: https://www.nejm.org/doi/full/10.1056/nejmoa1801005

FLAURA: https://www.nejm.org/doi/full/10.1056/NEJMoa1913662

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Michael and Josh discuss the scourge that is metastatic mesothelioma. This genuinely awful disease continues to inflict significant mortality and morbidity on patients exposed to asbestos worldwide. One of our more grim episodes thus far, but never fear; we have still crammed in more dad jokes than one can wave a bag of chemotherapy at.

Links to papers discussed in this episode (subscription may be required):

Vogelzang et al (2003): https://ascopubs.org/doi/10.1200/jco.2003.11.136

CHECKMATE-743: https://www.thelancet.com/article/S0140-6736(20)32714-8/fulltext

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Editor's Note: the background noise is wind from a storm that hit Melbourne on the day of recording. It is not a cat being put through a blender

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Some oncologists may have already started counting down to ASCO 2025. However, Michael and Josh are still digesting the interesting world of ASCO 2024, specifically upper GI and Hepatobiliary Cancers. Like the eponymous lead of the 1992 classic Aladdin, several diamonds lie in the rough.

We cover perioperative FLOT in the metastatic setting, but most excitingly, it is a potentially new groundbreaking treatment for hepatocellular carcinoma.

Links to studies discussed in this episode (subscription may be required)

ECOG-ACRIN EA2174: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

ROTG 0848: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

CHECKMATE 9DW: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

RENAISSANCE: https://meetings.asco.org/2024-asco-annual-meeting/15831?presentation=231157%23231157

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, Josh and Michael discuss the incredible story of the treatment of metastatic melanoma, the immunotherapy revolution, and why this relegated a perfectly decent targeted therapy to second place on the podium. Join us for a titanic battle on a par with Macbeth vs Macduff, Rocky Balboa vs Apollo Creed, or Regina George vs that bus...

Links to papers discussed (subscription may be required):

CHECKMATE-067: https://www.nejm.org/doi/full/10.1056/nejmoa1910836

COMBI-D: https://www.nejm.org/doi/full/10.1056/NEJMoa1904059

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Cover art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

In their inaugural episode, Michael and Josh discuss one of the most common cancers a budding oncologist will encounter: prostate cancer. But is there more to this cancer than meets the eye? Will they make sense of the whole confusing mess? Is this whole podcasting thing way too much for them to handle? Listen on to find out!

Links to papers discussed (subscription may be required):

CHAARTED: https://www.nejm.org/doi/full/10.1056/nejmoa1503747

ENZAMET: https://www.nejm.org/doi/full/10.1056/nejmoa1903835

For more episodes, resources and blog posts, visit inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Cover art courtesy of Taryn Silver

Music courtesy of AlexiAction: https://pixabay.com/users/alexiaction-26977400/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.